Custom Report

La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis and assessment reports can be prepared according to the specifications of the client from the pharmaceutical or biotechnology industry.

More info

ZUG, Switzerland I March 13, 2018 I Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today provided an update on the TACTT3 clinical trial with Keyzilen® in the treatment of acute inner ear tinnitus as well as the results from the Company’s Extraordinary General Meeting held on March 12, 2018.

TACTT3 Trial
Preliminary top-line data from the TACTT3 trial indicate that the study did not meet its primary efficacy endpoint of a statistically significant improvement in the Tinnitus Functional Score from baseline to Day 84 in the active treated group compared to placebo either in the overall population or in the otitis media subpopulation. The Company is investigating the outcomes, including those in the previously conducted sister trial TACTT2, and will provide an update in due course.

Extraordinary General Meeting
On March 12, 2018, the extraordinary general meeting of shareholders of Auris Medical Holding AG approved, among other items, the merger of the company with one of its subsidiaries. The merger has become effective on March 13, 2018, and results in a reverse split of 1 new share for 10 old shares. The post-merger common shares (CUSIP number H0381L104) of Auris Medical Holding AG are expected to begin trading on the Nasdaq Capital Market on March 14, 2018.

About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology. The company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is developing intranasal betahistine for the treatment of vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Capital Market under the symbol “EARS.”

SOURCE: Auris Medical

Post Views: 32